SignaBlok, Inc.

Preclinical studies of novel peptide inhibitors (SCHOOL peptides) will be presented in an oral session. Presentation will highlight company's approach to targeted peptide delivery and support development of programs in oncology, sepsis and arthritis.

SignaBlok, Inc. was awarded a new $223,013 SBIR Phase I grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to develop a novel approach for targeted therapy of rheumatoid arthritis.

SignaBlok, Inc. was awarded a new NIH SBIR Phase II grant totaling $1.34 million for continuing development of new nanotechnology-based atherosclerosis imaging. This award follows on the success of work completed during the Phase I grant.

Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis

SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancer

SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Cancer Institute (NCI) to develop novel and first-in-class agents in lung cancer.

SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a grant from the National Institutes of Health (NIH) to develop multifunctional nanoformulations for diagnostic imaging of atherosclerosis.

SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning).